{
    "organizations": [],
    "uuid": "66541b82ed14ad0da1ca7790a20a746798376908",
    "author": "",
    "url": "https://www.reuters.com/article/brief-verastem-presents-preclinical-data/brief-verastem-presents-preclinical-data-highlighting-the-effects-of-duvelisib-in-combination-with-immune-checkpoint-or-co-stimulatory-antibodies-in-b-cell-lymphoma-model-idUSFWN1PL18P",
    "ord_in_thread": 0,
    "title": "BRIEF-Verastem Presents Preclinical Data Highlighting The Effects Of Duvelisib In Combination With Immune Checkpoint Or Co-Stimulatory Antibodies In B Cell Lymphoma Model",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "#Market News January 26, 2018 / 8:37 PM / in 4 minutes BRIEF-Verastem Presents Preclinical Data Highlighting The Effects Of Duvelisib In Combination With Immune Checkpoint Or Co-Stimulatory Antibodies In B Cell Lymphoma Model Reuters Staff 1 Min Read \nJan 26 (Reuters) - Verastem Inc: \n* VERASTEM PRESENTS PRECLINICAL DATA AT ASCO-SITC HIGHLIGHTING THE SYNERGISTIC EFFECTS OF DUVELISIB IN COMBINATION WITH IMMUNE CHECKPOINT OR CO-STIMULATORY ANTIBODIES IN B CELL LYMPHOMA MODEL \n* VERASTEM - DATA SUPPORT EXPLORATION OF DUVELISIB IN COMBINATION WITH ANTI-PD-1/PD-L1 OR CO-STIMULATORY ANTIBODIES IN PATIENTS WITH B CELL MALIGNANCIES \n* VERASTEM INC - DUVELISIB IS BEING STUDIED IN OTHER HEMATOLOGIC MALIGNANCIES INCLUDING PERIPHERAL T CELL LYMPHOMA \n* VERASTEM INC - PLANS TO SUBMIT NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR DUVELISIBâ€‹ DURING Q1 2018 \n* VERASTEM INC - DUVELISIB ALONE, ANTI-PD-1 ALONE AND ANTI-OX40 ALONE EACH INDUCED TUMOR GROWTH DELAY \n* VERASTEM INC - WHEN DUVELISIB AND ANTI-PD-1 WERE COMBINED, STRONG ANTI-TUMOR SYNERGY WAS OBSERVED Source text for Eikon: Further company coverage:",
    "published": "2018-01-26T22:34:00.000+02:00",
    "crawled": "2018-01-26T22:51:39.011+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "market",
        "news",
        "january",
        "pm",
        "minute",
        "present",
        "preclinical",
        "data",
        "highlighting",
        "effect",
        "duvelisib",
        "combination",
        "immune",
        "checkpoint",
        "antibody",
        "b",
        "cell",
        "lymphoma",
        "model",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "verastem",
        "inc",
        "verastem",
        "present",
        "preclinical",
        "data",
        "highlighting",
        "synergistic",
        "effect",
        "duvelisib",
        "combination",
        "immune",
        "checkpoint",
        "antibody",
        "b",
        "cell",
        "lymphoma",
        "model",
        "verastem",
        "data",
        "support",
        "exploration",
        "duvelisib",
        "combination",
        "antibody",
        "patient",
        "b",
        "cell",
        "malignancy",
        "verastem",
        "inc",
        "duvelisib",
        "studied",
        "hematologic",
        "malignancy",
        "including",
        "peripheral",
        "cell",
        "lymphoma",
        "verastem",
        "inc",
        "plan",
        "submit",
        "new",
        "drug",
        "application",
        "food",
        "drug",
        "administration",
        "q1",
        "verastem",
        "inc",
        "duvelisib",
        "alone",
        "alone",
        "alone",
        "induced",
        "tumor",
        "growth",
        "delay",
        "verastem",
        "inc",
        "duvelisib",
        "combined",
        "strong",
        "synergy",
        "observed",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}